Bristol Myers Squibb
3Q Revenues: $11.6 billion (+10%)
3Q Earnings: $1.6 billion (-17%)
YTD Revenues: $34.4 billion (+9%)
YTD Earnings: $4.6 billion (+350%)

Comments: Growth in the quarter was driven by Revlimid, Eliquis, Opdivo and new products Reblozyl, Inrebic, Onureg, Zeposia, Breyanzi, and Abecema. Revlimid sales were $3.3 billion in the quarter, up 11%. Eliquis sales were $2.4 billion, up 15%. Opdivo sales were $1.9 billion, up 7%. Orencia sales were $870 million, up 5%. Pomalyst/Imnovid sales were up 10% to $851 million. Sprycel sales were $551 million, up 1%. Yervoy sales were up 15% to $515 million. Abraxane sales were down 22% to $266 million. Empliciti sales were down 15% to $82 million.
 
U.S. revenues increased 12% to $7.3 billion in the quarter, driven by higher demand for Revlimid, Eliquis and our new product portfolio. International revenues increased 8% to $4.3 billion in the quarter, driven by higher demand for Eliquis, Revlimid and Opdivo. When adjusted for foreign exchange impact, international revenues increased 6%. Research and development expenses increased 30% to $3.3 billion in the quarter primarily due to an in-process research and development (IPR&D) impairment charge.
 
Filings
In October, the European Commission approved Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma.
 
In August, Opdivo was approved by the FDA for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection, regardless of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.